Enanta Q3 FY26 net loss $19.5M; cash $211.5M; RSV and immunology programs on track

ENANTA PHARMACEUTICALS INC

Revenue $14.4M from MAVYRET royalties, down from $18.3M YoY; net loss $19.5M ($0.67/sh) vs $18.3M ($0.85/sh).
Cash and marketable securities $211.5M; runway into fiscal 2029; OMERS gets 54.5% of royalties through 2032.
Dosing started in LOTUS Phase 2b pediatric RSV trial of zelicapavir; topline expected 2027; RESOLVE to initiate in 4Q 2026.
EDP-978 Phase 1 topline data expected 4Q 2026; EPS-3903 IND filing targeted 2H 2026; MRGPRX2 candidate selection 2H 2026.
Federal Circuit affirmed invalidity of Pfizer patent; Enanta filed rehearing petition; UPC hearing set for Sept 29, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.